Table 2. Cytotoxicity of fluorine containing platinum(II) complexes given as mean ± SD in six human cancer cell lines in comparison with Oxaliplatin*.
| Compounds | IC50 (μM) | |||||
|---|---|---|---|---|---|---|
| HT29 | H460 | DU145 | A549 | SKOV3 | MCF7 | |
| Oxaliplatin | 5.05 ± 0.20 | 22.11 ± 0.17 | 2.05 ± 0.16 | 0.86 ± 0.09 | 8.54 ± 0.18 | 0.79 ± 0.11 |
| 5a | 0.53 ± 0.16 | 11.05 ± 0.11 | 5.98 ± 0.16 | 0.35 ± 0.17 | 16.66 ± 0.32 | 0.61 ± 0.13 |
| 5b | 2.16 ± 0.18 | 10.21 ± 0.15 | 2.60 ± 0.18 | 0.65 ± 0.10 | 2.22 ± 0.19 | 0.41 ± 0.09 |
| 5c | 1.07 ± 0.12 | 10.04 ± 0.15 | 5.11 ± 0.14 | 4.90 ± 0.16 | 22.05 ± 0.20 | 9.82 ± 0.12 |
*The IC50 value for Cisplatin in HT29 cells was 4.05 ± 0.11 μM. IC50 was evaluated by the MTS assay for 72 h. All compounds were tested in the same batch and the experiments were performed three times with five replicates. HT29 (human colon cancer cell line), H460 (human lung cancer cell line), DU145 (human prostate cancer cell line), A549 (human lung carcinoma), SKOV3 (human ovarian cancer cell line), MCF7 (human breast cancer cell line).